Showing results (341-350 of 384) with videos related to
Sort By:
Pageof 39
BMJ Open|April 3, 2023
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injuryPeter Pickkers, Derek C Angus, Jacques Arend, et al.BMJ Open|March 4, 2022
Ventilation management and outcomes in out-of-hospital cardiac arrest: a protocol for a preplanned secondary analysis of the TTM2 trialChiara Robba, Niklas Nielsen, Josef Dankiewicz, et al.Clinical Pharmacology and Therapeutics|March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib StudyTim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.Journal of Vascular Surgery. Venous and Lymphatic Disorders|July 16, 2021
Surgical resection and graft replacement for primary inferior vena cava leiomyosarcoma: A multicenter experienceMichael Nooromid, Randall De Martino, Francesco Squizzato, et al.Critical Care (London, England)|July 30, 2016
Ebola virus disease and critical illnessAleksandra Leligdowicz, William A Fischer, Timothy M Uyeki, et al.American Heart Journal|September 2, 2019
Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial-Rationale and designJosef Dankiewicz, Tobias Cronberg, Gisela Lilja, et al.Critical Care Explorations|June 14, 2021
Dysnatremia and 6-Month Functional Outcomes in Critically Ill Patients With Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort StudyJeremy Cohen, Anthony Delaney, James Anstey, et al.Trials|October 8, 2020
Targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest: a statistical analysis planJanus Christian Jakobsen, Josef Dankiewicz, Theis Lange, et al.Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.Nature Medicine|April 1, 2022
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adultsBen Killingley, Alex J Mann, Mariya Kalinova, et al.Pageof 39